title: Single center experience of a new intensive induction therapy for ewing's family of tumors: feasibility, toxicity, and stem cell mobilization properties.
abstract: OBJECTIVE
  To examine the feasibility, tolerability, and toxicity of an intensified induction regimen (vincristine, ifosfamide, doxorubicin, and etoposide [VIDE]) in patients with newly diagnosed Ewing's family of tumors (EFT); to assess ability to maintain dose-intensity, and predictability of peripheral-blood stem cell mobilization.
  
  
  METHODS
  Thirty patients were treated with vincristine 1.4 mg/m2 (maximum 2 mg) on day 1, doxorubicin 20 mg/m2, ifosfamide 3 g/m2 plus mesna and etoposide 150 mg/m2 on days 1 to 3. Cycles were given every 21 days for up to six cycles.
  
  
  RESULTS
  One-hundred and seventy cycles of VIDE were given. The median treatment interval was 21 days (21 to 42) and nadir count: hemoglobin 8.3 (6.3 to 11.9), neutrophils 0.045 (0.0 to 2.1), and platelets 45 (3 to 343). There were 96 episodes of infection requiring hospitalization (56%). Growth factor support reduced infectious complications by 34%. Etoposide dose was reduced, or omitted, in 24% of cycles. Four patients did not complete six cycles due to unacceptable toxicity and one patient progressed on treatment. Twenty patients underwent peripheral-blood stem cell harvesting, 15 after cycle 3, and five after cycle 4. Median CD34+ yield was 4.6 x 106/kg per patient (1.8 to 14.5). Overall response to treatment, measured in 24 patients, was 88%. Seven of 11 patients undergoing surgery achieved greater than 90% necrosis of tumor (64%).
  
  
  CONCLUSIONS
  VIDE is an effective induction regimen with substantial but acceptable toxicity that allows predictable mobilization of stem cells. Maintenance of dose-intensity is feasible in the majority of patients. Growth factors play a role in maintaining dose-intensity and reduce infectious complications.
authors.affiliation: Meyerstein Institute of Oncology, Middlesex Hospital, University College London Hospitals National Health Service Trust, Mortimer St, London, United Kingdom.
authors.forename: S J
authors.initials: SJ
authors.lastname: Strauss
authors.forename: A
authors.initials: A
authors.lastname: McTiernan
authors.forename: D
authors.initials: D
authors.lastname: Driver
authors.forename: M
authors.initials: M
authors.lastname: Hall-Craggs
authors.forename: A
authors.initials: A
authors.lastname: Sandison
authors.forename: A M
authors.initials: AM
authors.lastname: Cassoni
authors.forename: A
authors.initials: A
authors.lastname: Kilby
authors.forename: M
authors.initials: M
authors.lastname: Michelagnoli
authors.forename: J
authors.initials: J
authors.lastname: Pringle
authors.forename: J
authors.initials: J
authors.lastname: Cobb
authors.forename: T
authors.initials: T
authors.lastname: Briggs
authors.forename: S
authors.initials: S
authors.lastname: Cannon
authors.forename: J
authors.initials: J
authors.lastname: Witt
authors.forename: J S
authors.initials: JS
authors.lastname: Whelan
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005240:Feasibility Studies; D005260:Female; D019650:Hematopoietic Stem Cell Mobilization; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008297:Male; D015080:Mesna / Q000008:administration & dosage; D009367:Neoplasm Staging; D012512:Sarcoma, Ewing / Q000188:drug therapy*; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D015080:Mesna; D007069:Ifosfamide